Introduction
Nucleic acids are an important tool for the development of genome-based therapeutic strategies. The sequencing of the human and other genomes enables the development of therapeutic DNA which broadens the spectrum of pharmacologic intervention in disease. In gene therapy, therapeutic DNA is designed to replace defective genes or to provide new genes. Vaccination with naked DNA induces antigen-specific immune responses. 1 Antisense oligodeoxynucleotides (ODN) block protein synthesis by sequence-specific hybridization to the corresponding mRNA. [2] [3] [4] All these concepts are based on the view of DNA as a blueprint of proteins. However, DNA is more than that. Recently it has been discovered that unmethylated CpG dinucleotides in particular base contexts ('CpG-motifs') are recognized by the immune system as a danger signal. [5] [6] [7] [8] Recognition as danger by the immune system is based on under-representation and methylation of CpG dinucleotides in vertebrate DNA compared with bacterial DNA. Synthetic DNA and DNA generated in bacterial systems contain unmethylated CpG motifs which stimulate the immune system. This has clear implications for DNA-based therapeutic strategies. Immune activation by CpG motifs in DNA used for gene therapy is unwanted since activated immune cells recognize and eliminate transfected cells expressing newly acquired antigens. In contrast, concomitant CpGmediated immune stimulation is required in naked DNA vaccination for the stimulation of a specific immune response. 9, 10 CpG motifs in antisense ODN can alter biologic functions in addition to the antisense mechanism itself. 11, 12 Depending on the target protein and the target disease, this can be beneficial or unwanted.
In animal models, ODN with immunostimulatory CpG motifs have been shown to be of therapeutic value as adjuvants for conventional and therapeutic vaccination against infectious disease 13, 14 and tumors. 15, 16 CpG DNA biases the immune response to a Th1-like pattern (IL-12, IFN-␥, IgG 2a ). 14, 17, 18 This shift is useful for the treatment of allergic disease 19 and to prevent or overcome infections with parasites or intracellular bacteria. 20, 21 In mice, the adjuvant effect of CpG DNA is equally as potent as the complete Freund's adjuvant. 15, 18 Complete Freund's adjuvant consists of heat-killed dried Mycobacterium tuberculosis which includes mycobacterial DNA and components of the cell membrane including endotoxins. [22] [23] [24] Bacterial DNA has been known for its immunostimulatory activity for many years, 25, 26 but the CpG-mediated mechanism responsible for this activity was unknown until recently. 5 Endotoxins in complete Freund's adjuvant contribute to its toxicity 27 which hamper its therapeutic use in humans in contrast to mice which are less sensitive to LPS.
CpG effects on the immune system are well characterized in mice. CpG stimulates murine macrophages to release IL-12 and tumor necrosis factor (TNF), 28, 29 two key cytokines in immune regulation. 30, 31 Murine NK cells produce IFN-␥ in response to CpG-induced TNF and IL-12 production by macrophages. [32] [33] [34] IFN-␥ in turn costimulates macrophages for enhanced TNF and IL-12 synthesis. 29 Murine B-lymphocytes are directly activated by CpG to proliferate and to secrete Ig and IL-6. 5, [35] [36] [37] In contrast, in humans CpG-mediated induction of cytokines 9, 34, 38, 39 and induction of B cell proliferation [40] [41] [42] is less well characterized. Two major differences between mouse and human hinder the direct transfer of experimental settings from mice to humans: (1) the optimal flanking bases of the CpG dinucleotide are different in humans (A Krieg, unpublished data); and (2) human immune cells respond to 2 logs lower endotoxin levels than mouse cells. To evaluate immune effects of CpG DNA in humans we pursued the following strategy in vitro: (1) we examined E. coli DNA, which contains a variety of immunostimulatory CpG motifs, to estimate the capability of human immune cells to respond to CpG; (2) we compared ODN with CpG motifs to E. coli DNA; and (3) we analyzed the contribution of CpG and LPS to immune activation, using a newly developed, highly sensitive assay for LPS.
In the present study we show that: (1) CpG DNA elicits immune responses in human immune cells; (2) CpG-and LPS-mediated immune response can be distinguished by the time course of cytokine induction; and (3) CpG DNA and LPS act synergistically to induce inflammatory cytokines.
Results
Detection of small amounts of endotoxin in DNA samples In previous studies, we and others have reported that CpG motifs in DNA induce synthesis of the pro-inflammatory cytokines TNF and IL-6 by murine spleen cells. 36 The current studies were performed to investigate the cytokine production by different cell types in human PBMC in response to E. coli DNA (containing CpG motifs), calf thymus DNA (nonstimulatory DNA) and LPS as a positive control. To perform the analysis we used intracellular cytokine staining which allows the detection of cytokine synthesis on the single cell level.
Freshly prepared human PBMC were incubated with these stimuli for 4 h in the presence of brefeldin A (1 g/ml) to block cytokine secretion (see Materials and methods section). Detection of LPS by this method was highly sensitive. In PBMC from three different donors, the maximal dose of LPS (10 ng/ml) induced an average of 96.0% ± 1.2% monocytes (range, 94.2 to 97.6%, n = 3) to stain positive for TNF (one typical donor shown in Figure 1 , first row, first plot: 94%). We found a dosedependent decrease in TNF-positive monocytes for lower concentrations of LPS. The lower detection limit of this assay was 0.006 ng/ml LPS ( Figure 1 , third row, first plot: 3.7% compared with 0.9% without LPS).
In PBMC stimulated by 30 g/ml E. coli DNA, 93% of monocytes stained positive for TNF (Figure 1 , third row, second plot), equally effective to 10 ng/ml LPS ( Figure 1 , first row, first plot). However, there was a high background level of 34% TNF-positive cells induced by 30 g/ml calf thymus DNA which was expected to be nonstimulatory based on our previous studies with murine cells (Figure 1 , third row, third plot). Since human monocytes are far more sensitive to endotoxin than murine cells, we speculated that low levels of endotoxin contamination may be responsible for this TNF induction. In the LAL assay, the E. coli DNA sample contained 1.01 EU/ml, the calf thymus DNA sample 0.14 EU/ml endotoxin (final DNA concentration 30 g/ml). Surprisingly, by careful purification of both DNA samples (see Materials and methods section), TNF induction disappeared completely for both E. coli DNA and calf thymus DNA (Figure 1 , third row, second and third plot, A: unpurified DNA, B: purified DNA; compare with control without LPS: 0.9% TNF positive cells). Importantly, even DNA samples already negative in the LAL assay (Ͻ0.03 EU/ml) induced considerable TNF staining of monocytes, showing that the LAL assay is less sensitive compared with endotoxin detection by TNF staining with flow cytometry. Purified E. coli DNA and ODNs were also found to be negative for induction of TNF expression in human PBMC during the first 4 h (Figure 1 , fourth row, second and third plot).
CpG DNA-induced TNF and IL-6 synthesis is delayed compared with LPS These results suggested a lack of TNF synthesis in human PBMC in response to endotoxin-free E. coli DNA or CpG ODN (LPS below 0.006 ng/ml). However, in these experiments TNF synthesis was measured only during the first 4 h. Adding brefeldin A (blockade of protein secretion) during later time spans allows the detection of TNF synthesis during later time periods. Between 4 and 10 h, the percentage of TNF-positive monocytes induced by 10 ng/ml LPS was still high (98%, Figure 2a (ODN 1760 (ODN , 1908 (ODN , 2059 (ODN and 2077 were found to be endotoxin-negative (separate experiment, lower panel).
Figure 2 CpG DNA-mediated induction of TNF and IL-6 in monocytes is delayed compared with LPS. PBMC (1 × 10 6 cells/ml) were incubated in the presence of 10 ng/ml LPS (first column), 30 g/ml E. coli DNA (second column) and without stimulus (third column). Brefeldin A (1 g/ml) was added at 4 h or 18 h to block cytokine secretion. TNF (a) and IL-6 (b) synthesis from 4 to 10 h and from 18 to 24 h were determined in CD14-positive monocytes by intracellular staining of TNF and IL-6 and detection of positive cells by flow cytometry. E. coli DNA induced TNF and IL-6 synthesis between 18 and 24 h but not during earlier time spans. At the time LPS-induced IL-6 synthesis is still sustained (18 to 24 h) LPS-induced TNF synthesis already disappeared.
showed a sustained production up to at least 24 h. E. coli DNA (30 g/ml) stimulated 19% of the monocytes to produce IL-6 between 18 and 24 h (Figure 2b , second row, second plot). Similar to E. coli DNA-induced TNF, E. coli DNA-induced IL-6 production was not enhanced at earlier time-points.
Neither E. coli DNA nor LPS induced detectable TNF and IL-6 expression in B-lymphocytes or T-lymphocytes. In contrast, a combination of the stimuli phorbol 12-myristate 13-acetate (PMA, 50 ng/ml) and calcium ionophore A23187 (250 ng/ml) as a positive control induced 14.6% of the B-lymphocytes and 7.1% of the T-lymphocytes to stain positive for TNF demonstrating that the assay has sufficient sensitivity to detect this (data not shown). Therefore the source of CpG DNA-induced TNF and IL-6 production in human PBMC appears to be monocytes. However, monocyte-restricted TNF and IL-6 production does not exclude the involvement of other cell types in the CpG response.
IL-6 production in response to CpG DNA is concentration dependent and CpG-specific Using intracellular cytokine staining as described above, it became clear that TNF and IL-6 synthesis in PBMC during the first 4 h after stimulation was induced by endotoxin. In contrast, analysis of highly purified DNA samples revealed that CpG DNA-mediated TNF and IL-6 expression was delayed compared with that induced by endotoxin. These purified DNA samples were used to stimulate PBMC for 24 h. To confirm that the IL-6 produced was secreted, IL-6 production was measured in the supernatant by ELISA (lower detection limit 10 pg/ml). All reagents used for cell culture were essentially endotoxin-free since cells incubated for 24 h without stimulus produced no detectable amounts of IL-6 (Ͻ10 pg/ml). E. coli DNA-induced IL-6 production was found to be CpGspecific and concentration dependent (Figures 3 and 4) . In seven independent experiments, E. coli DNA (30 g/ml) induced the production of an average of 409 pg/ml IL-6 (s.e.m. ± 75, range 182 to 670 pg/ml, n = 7) (Figure 3 ). In comparison, 0.1 ng/ml LPS induced the production of an average of 1283 pg/ml IL-6 (s.e.m. ± 355, range 475 to 3136 pg/ml, n = 7). Calf thymus DNA (30 g/ml) induced no IL-6 synthesis (Ͻ10 pg/ml). In addition to calf thymus DNA, chloroquine was used to control for CpG specificity since it has been reported to block CpG-but not LPS-mediated cytokine expression selectively. 38, 43 Chloroquine blocked E. coli DNA-induced IL-6 expression by 58% (52 to 65%, n = 2, not shown in Figure) . In contrast, LPS-induced IL-6 was only slightly reduced by chloroquine (9%, 5 to 14%, n = 2). E. coli DNA induced IL-6 expression in a concentration-dependent manner. Lowering the concentration of E. coli DNA from 30 g/ml to 10 g/ml reduced IL-6 levels from 315 pg/ml to 18 pg/ml (Figure 4 ).
CpG DNA and LPS synergize for induction of IL-6 expression Since we found that CpG DNA and LPS show a different time-course of inducing cytokine expression, it is possible that CpG DNA and LPS use different pathways for their stimulatory activity. Therefore we examined if CpG DNA and LPS induce cytokine expression synergistically by adding 30 g/ml E. coli DNA to increasing concentrations of LPS ( Figure 5 ). The lowest LPS concentration which induced detectable IL-6 expression was 0.025 ng/ml (185 pg/ml, 53 to 316 pg/ml, n = 2). E. coli DNA alone induced 364 pg/ml IL-6 (324 to 404 pg/ml, n = 2) The addition of 30 g/ml E. coli DNA to 0.025 ng/ml LPS increased IL-6 production 3.5-fold compared with the sum of IL-6 induced by LPS and E. coli DNA alone ( Figure 5 ). This synergistic effect was found for all tested LPS concentrations, but was more pronounced for lower LPS concentrations. Even the lowest tested LPS concentration, 0.0125 ng/ml, which itself did not induce detectable amounts of IL-6, enhanced E. coli DNA-mediated IL-6 synthesis by 2.6-fold (from 364 pg/ml for E. coli DNA alone to 935 pg/ml, range 620 to 1250 pg/ml, n = 2). This synergistic effect was CpG-specific, since calf thymus DNA (30 g/ml) did not influence LPS-stimulated IL-6 synthesis (tested for LPS concentrations 0.003 to 0.1 ng/ml, not shown).
CpG DNA induces strong ICAM-1 expression in monocytes The adhesion molecule ICAM-1 is an activation marker of monocytes and regulates intercellular communication between leukocytes. To investigate the possible effects of CpG DNA on ICAM-1 expression, human PBMC were incubated with E. coli DNA or LPS, and ICAM-1 expression was examined on CD14-positive monocytes by flow cytometry. We found that ICAM-1 is strongly upregulated in the presence of CpG DNA or LPS in a time-dependent manner. ICAM-1 expression increased continuously for both E. coli DNA and LPS until 48 h of stimulation (latest time-point tested). As soon as 6 h after stimulation ICAM-1 expression was enhanced for both E. coli DNA and LPS. Compared with E. coli DNA, LPSinduced ICAM-1 expression was higher at 6 h and at 24 h. However, at 48 h, E. coli DNA-induced ICAM-1 expression was even higher than LPS-induced ICAM-1. In all of the following experiments we measured ICAM-1 expression 48 h after stimulation.
Maximal ICAM-1 expression was induced by 0.1 ng/ml LPS with no further increase for higher doses of LPS. In the presence of 1 ng/ml LPS, the mean fluorescence intensity (MFI) of ICAM-1 staining was increased 3.6-fold (50.6 ± 6.3, 35.7 to 66.3, n = 5, P = 0.001) compared with the control without stimulus (13.9 ± 1.9, 10.3 to 20.6, n = 5) ( Figure 6 ). E. coli DNA seemed to induce even higher expression of ICAM-1 (MFI: 63.3 ± 8.3, range 41.1 to 85.8, n = 5, P Ͻ 0.001), but the difference from 1 ng/ml LPS was not statistically significant (P = 0.2). A total of five experiments demonstrated that the induction of ICAM-1 expression by E. coli DNA (30 g/ml) was not significantly different from ICAM-1 induction by 1 ng/ml LPS. The effect of E. coli DNA was CpG-specific, since ICAM-1 expression by calf thymus DNA was lower (MFI: 25 ± 3.9, 17.7 to 36.6, n = 5) although still enhanced compared with the control without stimulus (13.9 ± 1.9, 10.3 to 20.6, n = 5).
E. coli DNA-mediated ICAM-1 expression was found to be concentration-dependent. As low as 2 g/ml E. coli DNA increased ICAM-1 expression two-fold compared with the control without stimulus (27.0 ± 9.3 versus 13.5 ± 2.9, n = 2) (Figure 7) .
No synergistic effect of CpG DNA and LPS on ICAM-1 induction E. coli DNA and LPS are approximately equally effective in enhancing ICAM-1 expression in monocytes. However, in contrast to IL-6 induction, the addition of increasing concentrations of LPS to E. coli DNA (30 g/ml) did not further increase ICAM-1 expression by E. coli DNA alone (Figure 8 ). The addition of calf thymus DNA did 899 not change the dose-dependent increase of LPS-mediated ICAM-1 induction, adding further evidence for the CpG specificity of E. coli DNA-induced ICAM-1 induction (Figure 8 ). To exclude that 30 g/ml E. coli DNA alone induces the maximum amount of ICAM-1 expression, we tested a submaximal dose of E. coli DNA (7.5 g/ml). Again, the addition of LPS did not increase the effect of 7.5 g/ml E. coli DNA, although ICAM-1 expression by 7.5 g/ml E. coli DNA was not maximal (MFI 58.0) compared with ICAM-1 induction by 30 g/ml E. coli DNA (MFI 85.8) (not shown in Figure) .
Induction of IL-6 and ICAM-1 expression is CpG-specific as tested by ODN with CpG motifs We hypothesized that the specific induction of IL-6 and ICAM-1 expression by E. coli DNA compared with calf thymus DNA may be due to their different content of unmethylated CpG motifs, which have been reported to account for the immunostimulatory effects of E. coli DNA on murine cells. 36 To prove CpG specificity as opposed to some other property of E. coli DNA, we tested two ODN with CpG motifs and their corresponding non-CpG control ODN for their capability to induce IL-6 and ICAM-1 expression in a CpG-dependent manner. The ODN 1760 is a nuclease resistant completely phosphorothioate-modified 20-mer and ODN 1908 is the corresponding control. The ODN 2059 (24-mer) is unmodified and ODN 2077 is the corresponding control. These purified ODNs were found to be endotoxin-free in flow cytometry (endotoxin lower than 0.006 ng/ml) ( Figure 1 , fourth row, second and third plot).
Because of their higher stability, the phosphorothioatemodified ODN (1760 and 1908) were used in a lower concentration (6 g/ml) than the unmodified ODN (2059 and 2077, 30 g/ml). Furthermore, the unmodified ODN were added repeatedly (0, 4 and 8 h). Both CpG ODN induced IL-6 expression after 24 h of incubation (1760: 93 pg/ml, 87 to 96 pg/ml; 2059: 60 pg/ml, 58 to 61 pg/ml, n = 2) ( Figure 9 ). No IL-6 expression was induced by the control ODN (below 10 pg/ml). For the unmodified ODN 2059, the repeated addition was necessary. A single addition of 30 g/ml 2059 induced no 
Discussion
CpG-mediated immune activation in mice is well characterized but information about CpG effects on human immune cells is far more limited. A better understanding of CpG effects in humans is required to transfer knowledge acquired from mouse studies to human therapeutic strategies.
Because human PBMC respond to 2 logs lower endotoxin levels than murine macrophages, we were not able to distinguish between CpG DNA-and LPS-mediated effects in the presence of even minor contamination of the DNA sample with LPS. After intense purification of E. coli DNA, a different time course of CpG-and LPSmediated cytokine production was found using flow cytometry to measure cytokine synthesis by individual monocytes. LPS induced a rapid TNF and IL-6 synthesis during the first 4 h after stimulation. After 18 h no LPSmediated TNF synthesis could be detected in the monocytes, while IL-6 production was still elevated. In contrast, the cytokine response to E. coli DNA was delayed and could not be detected earlier than 10 h after stimulation. The rapid TNF response to LPS during the first 4 h makes it possible to detect small amounts of LPS even in the presence of CpG motifs, because CpG-stimulated TNF appeared at later time-points. Detection of TNFpositive monocytes by flow cytometry allowed us to detect as low as 0.006 ng/ml (0.0014 EU/ml) LPS. This technique was used to monitor proper purification of DNA samples down to a purification degree where nonCpG-mediated stimulation of monocytes was excluded.
With purified DNA samples we found potent and CpG-specific immune effects of both E. coli DNA and ODN with CpG motifs. E. coli DNA and CpG ODN induced expression of the proinflammatory cytokines TNF and IL-6 and the adhesion molecule ICAM-1 in human monocytes. IL-6 and TNF production could not be detected in PBMC cell types other than monocytes. While CpG-induced IL-6 expression was consistent but lower than LPS-stimulated IL-6, ICAM-1 induction by CpG DNA was even higher than LPS-induced ICAM-1 expression. Furthermore, CpG ODN induced ICAM-1 expression in the same range as E. coli DNA. In contrast, E. coli DNA stimulated approximately four times higher IL-6 production than CpG ODN.
CpG-mediated upregulation of ICAM-1 on leukocytes has not been described to date. The adhesion molecule ICAM-1 is a key mediator for the interaction of immune cells. Blockade of ICAM-1 by specific antibodies inhibits the mixed lymphocyte reaction.
44 Specific downregulation of ICAM-1 by antisense ODN improves Crohn's disease. 45 ICAM-1-mediated cell contact is required for the interaction between T-lymphocytes and antigenpresenting cells 46 and for transepithelial migration of immune cells. 47 ICAM-1, acting as a costimulatory molecule, is required but not sufficient for many inflammatory responses suggesting that its increased expression in response to CpG may be important in mediating the biologic effects of CpG DNA.
We found a synergism of CpG and LPS for induction of IL-6 synthesis. This synergism might be involved in human disease. In sepsis, bacterial DNA present in the circulation could trigger excessive cytokine production and increase the risk of a fatal outcome of disease. Even with the lower LPS sensitivity in mice, CpG and LPS were found to synergize for the production of TNF in vivo. 48 Recently it was shown that CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract suggesting that CpG DNA may play an important pathogenic role in inflammatory lung disease. 49 In chronic inflammatory bowel disease, the loss of the mucosal integrity could expose immune cells to both LPS and bacterial DNA present at high levels in the lumen of the bowel. This may trigger periodic aggravation of the disease. In fact, all animal models of colitis described to date require the presence of bacteria in the bowel. 50, 51 Furthermore, our results are relevant for the development of CpG DNA as adjuvants for vaccination in humans. Both endotoxins and CpG DNA are constituents of the complete Freund's adjuvant, [22] [23] [24] which is a potent adjuvant in mice but can not be used in humans because of its toxicity. The reason may be the higher LPS sensitivity in humans compared with mice combined with the synergy of CpG DNA and LPS to stimulate toxic inflammatory cytokines. The finding that CpG DNA alone has strong adjuvant activity supports the view that bacterial DNA contributes to the adjuvant activity of the complete Freund's adjuvant. 52 Indeed in mice, CpG ODNs are equally efficient adjuvants compared with the complete Freund's adjuvant to promote specific antibody response. 15 CpG ODN are currently being developed as adjuvants for prophylactic and therapeutic vaccination against infectious disease and tumors in humans. The presence of CpG motifs contributes to other DNAbased therapeutic strategies. CpG motifs are necessary for effective vaccination with naked DNA. 9 The presence of CpG motifs in antisense ODN may affect their biologic activity. 12 Immune activation by CpG motifs is usually unwanted in gene replacement therapy. However, both viral DNA (adenovirus, retrovirus) and bacteria-derived plasmid DNA used for gene therapy contain different amounts of unmethylated immunostimulatory CpG motifs. In addition, bacteria-derived plasmids usually contain considerable amounts of LPS. The experimental procedure described in this study provides a valuable tool for the quality control of therapeutic DNA preparations with respect to both CpG and LPS.
In conclusion, our study is the first to show the ability of the human immune system to respond to CpG DNA by an activation pattern which is different from LPS. The set of immune responses stimulated by CpG in human cells may be more favorable than the LPS response for therapeutic purposes in terms of lower toxicity and a sustained response. Our results stress the fact that complete elimination of LPS from therapeutic DNA is required in humans, while the presence of LPS might not affect the efficacy of therapeutic DNA in mice because of their lower LPS sensitivity. This is especially important in transferring therapeutic strategies from mouse models to humans.
Materials and methods
Oligodeoxynucleotides and DNA Unmodified (phosphodiester) and modified nucleaseresistant (phosphorothioate) ODN were purchased from Operon Technologies (Alameda, CA, USA). The sequences used are: 1760 (20-mer), 5Ј-ATA ATC GAC GTT CAA GAA AG-3Ј, completely phosphorothioatemodified to increase nuclease resistance; 1908 (20-mer), 5Ј-ATA ATA GAG CTT CAA GCA AG-3Ј, is the corresponding phosphorothioate control non-CpG ODN for 1760; 2059 (24-mer), 5Ј-TCG TCG TTT TGT CGT TTT GTC GTT-3Ј, phosphodiester; 2077 (22-mer), 5Ј-GCT AGC TTT AGA GCT TTA GAG CTT-3Ј, the corresponding phosphodiester control ODN for 2059. The CpG ODN were used as examples of immune stimulatory sequences. E. coli DNA and calf thymus DNA were purchased from Sigma Chemical, St Louis, MO, USA. E. coli and calf thymus DNA were made single stranded by boiling for 10 min, followed by cooling on ice for 5 min, before use. DNA samples were diluted in TE-buffer using pyrogen-free reagents.
DNA samples were purified for our initial studies by extraction with phenol-chloroform-isoamyl alcohol (25/24/1) and ethanol precipitation. Where indicated, endotoxin was removed by repeated extraction with Triton x-114 (Sigma Chemical). Before Triton x-114 extraction, 30 g/ml E. coli DNA contained 1.0 EU/ml endotoxin and 30 g/ml calf thymus DNA 0.14 EU/ml endotoxin (in the LAL assay) (LAL assay; BioWhittaker, Walkersville, MD, USA). After Triton x-114 extraction, endotoxin could no longer be detected in the LAL assay (Ͻ0.03 EU/ml for both DNA samples). Purification by Triton x-114 was performed as follows: 25 mg DNA were 901 diluted in 40 ml pyrogen-free water, 400 l Triton x-114 was added and the solution mixed at 4°C for 15 min and placed on ice for an additional 20 min. Subsequently, the solution was incubated for 25 min at 55°C (cloudy upper layer and clear lower Triton x-114 layer) and centrifuged for 20 min (600 g, 37°C) . The upper phase was transfered to a new tube, 400 l Triton x-114 was added, and previous steps were repeated until the DNA was found to be endotoxin-free by intracellular TNF staining and flow cytometry as described below.
Detection of endotoxin
The activity of LPS is standardized by the FDA using the limulus amebocyte lysate (LAL) assay (EU/ml). The lower detection limit of the LAL assay is 0.1 EU/ml. The measurement of concentrations between 0.1 and 0.01 EU/ml is possible but shows variability. The LPS sample used in our studies (from Salmonella typhimurium, Sigma Chemical) had an activity of 4.35 ng/EU in a standardized LAL assay. In our hands the lower detection limit of the LAL assay was 0.03 EU/ml which correlates to 131 pg/ml of our LPS sample. However, 25 pg/ml LPS stimulated considerable amounts of IL-6 in PBMC. Using flow cytometry and intracellular TNF staining (see section on intracellular staining of TNF and IL-6), the lower detection limit of LPS was 6 pg/ml (0.0014 EU/ml). Where indicated, all ODN and DNA samples have been purified until no endotoxin could be detected by flow cytometry and TNF staining (below 6 pg/ml or 0.0014 EU/ml).
Cell preparation and cell culture
Human peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical) as described. 53 Cells were suspended in RPMI 1640 culture medium supplemented with 10% (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT, USA), 1.5 mm l-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (all from Gibco BRL, Grand Island, NY, USA) (complete medium). All compounds were purchased endotoxintested. Viability was determined before and after incubation with ODN by trypan blue exclusion (conventional microscopy) or by propidium iodide exclusion (flow cytometric analysis). In all experiments, 96 to 99% of cells were viable.
Freshly prepared PBMC (final concentration 1 × 10 6 cells/ml) were cultured in complete medium in the presence of different stimuli in a 5% CO 2 humidified incubator at 37°C. Cell cultures were performed in 48-well plates (800 l) or 96-well plates (200 l). At the indicated time-points, supernatants for the IL-6 ELISA were removed and kept at −20°C, or cells were harvested for flow cytometry as described below.
Surface antigen staining
All antibodies used were purchased from Pharmingen, San Diego, CA, USA. Surface antigen staining and analysis by flow cytometry was performed as previously described. 54 To identify monocytes in PBMC, a FITClabeled mouse anti-human mAb against CD14 (M5E2) was used. ICAM-1 expression was examined using a phycoerythrin (PE)-labeled mouse anti-human mAb against ICAM-1 (HA58). FITC-labeled IgG 1 , (MOPC-21) and PE-labeled IgG 2b , (27) (28) (29) (30) (31) (32) (33) (34) (35) were used to control for specific staining.
Intracellular staining of TNF and IL-6
For intracellular cytokine staining, PBMC (final concentration 1 × 10 6 cells/ml) were incubated in the presence of brefeldin A (final concentration 1 g/ml, stock solution 1 mg/ml in ethanol, Sigma Chemical) to block protein secretion during the indicated time spans. After incubation, cells were harvested and resuspended in 100 l of buffer A (Fix and Perm Kit, Caltag Laboratories, Burlingame, CA, USA), incubated at room temperature for 15 min, 2 ml PBS was added and cells were centrifuged (400 g, 5 min, 4°C). The supernatant was removed completely and cells were resuspended in 100 l buffer B (Fix and Perm Kit) and 10 l of either the PE-labeled mouse anti-human TNF mAb (MAb11) or the PE-labeled rat anti-human IL-6 mAb (MQ2-6A3). After 15-min incubation at room temperature in the dark, 2 ml PBS was added and the cells were centrifuged (400 g, 5 min, 4°C). Cells were resuspended in 100 l ice-cold PBS and 10 l of a FITC-labeled mouse anti-human CD14 mAb (M5E2) and incubated on ice in the dark for 15 min. Cells were washed with 2 ml ice-cold PBS and examined by flow cytometry.
Flow cytometry
Flow cytometric data of 5000 cells per sample (cells from the morphologic monocyte gate only) were acquired on a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA, USA). In two and three color flow cytometric analyses, spectral overlap was corrected by appropriate compensation. Fluorescence detector settings were adjusted, so that stained cells were on scale for each parameter. Non-viable cells were excluded from analysis by propidium iodide staining (2 g/ml). Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Stanford, CA, USA).
ELISA for IL-6
Flat-bottom Immulon-1 plates (Dynatech Laboratories, Chantilly, VA, USA) were coated with 100 l per well (4 g/ml) of anti-human IL-6 mAb (6708.111, R&D Systems, Minneapolis, MN, USA) diluted in PBS overnight at room temperature. The plates were washed with 0.05% Tween 20 in PBS, pH 7.4, and blocked by incubating with 300 l per well of PBS containing 1% BSA, 5% sucrose and 0.05% NaN 3 for 1 h at room temperature. After washing, 100 l of cell culture supernatants or recombinant human IL-6 (PharMingen) appropriately diluted in diluent buffer (0.1% BSA, 0.05% Tween 20 in Tris-buffered saline pH 7.3) were added in duplicates and incubated for 2 h at room temperature. Plates were washed, 100 l per well of the biotinylated mouse anti-human IL-6 mAb (R&D Systems) were added and plates were incubated for an additional 2 h followed by washes. Horseradish peroxidase-conjugated streptavidin (100 l per well) (Zymed, San Francisco, CA, USA) at a 1/20 000 dilution in diluent buffer was added and incubated at room temperature for 20 min followed by three washes. The plates were developed with 3,3Ј,5,5Ј-tetramethyl-benzidine (TMB, Sigma Chemical) (100 l per well) for 20 min. The reaction was stopped with 0.67 N H 2 SO 4 and plates were read on a microplate reader (Cambridge Technology, Watertown, MA, USA) set to 450 nm with wavelength correction to 570 nm. The lower detection limit was 10 pg/ml.
Statistical analysis
Data were expressed as means ± s.e.m. Statistical significance of differences was determined by the unpaired two-tailed Student's t test. Differences were considered statistically significant for P Ͻ 0.05. Statistical analyses were performed by using StatView 4.51 software (Abacus Concepts, Calabasas, CA, USA).
